Basic research is very useful, but it should be more geared toward application than it was before.

The center will be fully operational in two years' time, but probably in the middle of the year we will have a temporary laboratory of 4,000 square feet.

We don't know why, but there are some gradients of infection.

My proposal now is to test a vaccine first on people who have been infected, and if you show some efficacy at this level, you might be able to go further to study uninfected people in a population with a high rate of infection.

Basic research is very useful, but it should be more geared toward application than it was before.

Another interesting field, which is my own, is cofactors, not only to the disease but also to transmission. I am still puzzled by the fact that you get more sexual transmission in some ethnic populations. One way to answer this is to look for genetic factors.

It's clear that prevention will never be sufficient. That's why we need a vaccine that will be safe.